Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
about
My approach to the treatment of sclerodermaAnimal models of systemic sclerosis: their utility and limitations.A preliminary study of skin ultrasound in diffuse cutaneous systemic sclerosis: Does skin echogenicity matter?Molecular subsets in the gene expression signatures of scleroderma skin.Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.Hematopoietic cell transplantation for Crohn's disease; is it time?Current treatment options in systemic Sclerosis (Scleroderma).Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries.Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin diseaseLongitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosisAutologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phHigh-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyPatterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisFresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patientsOld medications and new targeted therapies in systemic sclerosis.Rheumatic disease among Oklahoma tribal populations: a cross-sectional study.Measuring illness behavior in patients with systemic sclerosisEvaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudyThe American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisScleroderma renal crisis, still a life-threatening complication.Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis.Histomorphometric analysis of cutaneous remodeling in the early stage of the scleroderma model.Skin involvement in systemic sclerosis.Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse sclerodermaRecognizing systemic sclerosis: comparative analysis of various sets of classification criteria.Rheumatic manifestations of skin disease.Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.Thermography Improves Clinical Assessment in Patients with Systemic Sclerosis Treated with Ozone Therapy.Evidence-based management of rapidly progressing systemic sclerosis.Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling.Biomarkers for skin involvement and fibrotic activity in scleroderma.Systemic sclerosis--challenges for clinical practice.Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.Quantitating skin fibrosis: innovative strategies and their clinical implications.
P2860
Q24618843-2F17E384-C7FB-4CDE-A00E-C33D8E1B494AQ28390528-E4C4BFA1-590F-4428-81CA-054D698D2AF4Q30359351-85059BB5-58EF-4AFA-A347-12306271D29DQ33354088-1AFD1766-F576-48A8-94E3-30766CB60BA0Q33536943-613261B2-2964-4D5C-BDB3-713EB6E3E52BQ33665990-5D49B449-FC57-43BE-ACF1-C5E14E0068C3Q33765551-9CC142DE-0D5A-41F6-8D21-4B9A8A637C35Q34017756-FF5115E0-4860-4932-BD30-1B86534C6872Q34567929-64C204E8-22E8-4041-82C5-00E719373CC2Q34905661-0DA65E00-CBAD-4807-989E-B22D9BAE3125Q35550480-D5F69779-D95B-429C-B5BD-42A1A0D65A73Q35554342-E8A401A6-DFA7-4A30-ADE1-695A494B3C8AQ35554404-267E2183-12EC-4D46-B3AE-39B5B4D5C6F6Q35878701-FD188C44-B16B-4178-9050-D33CC3276FC9Q35878705-90FA4D86-BAC5-434E-BE0F-1C8DAA9C9330Q35925071-6C61C4F0-9B25-40DC-88BE-E82D237A6F6AQ35977294-BD0DA426-704D-4693-B9F5-CD951766FCBFQ36040200-7389AABB-4715-465C-BA21-9204F24D5D19Q36154430-DFD35CA1-6193-4F3A-8C09-6B6FCA4DAA94Q36310765-C4FC23E5-C8D5-4D8E-8EAE-506510FD5453Q36625804-8BA39056-9C5B-4252-A555-578CAC71BE25Q36733749-CB5ABE25-F1D7-43A8-A440-C9390680A30DQ36758822-A5872D8E-2E8C-451A-A34E-3C7D302A9723Q36951036-2C2166D2-3B42-4F87-B433-00438515AB04Q37003312-5AF2D656-44B8-4297-BB91-8DA61439D5AAQ37248942-CA5E1EB7-3EFB-4579-8099-9AD35BAC043BQ37265837-0EF7A15B-955A-4146-A610-F781412C8E90Q37301159-5DE5148D-2F45-4713-93C4-6F49C918AFB2Q37324622-2B15D085-8BB3-485F-95CA-B0973BC548B3Q37434973-9B98393C-34E7-4DC3-9A66-B36AF2823FA1Q37590671-B5F58BC8-62A9-4800-ABC1-CC61CA92242DQ37620086-963C6BF9-6BBC-48D7-84C6-1B22269EF365Q37655603-EDAA1735-7948-46FC-AD46-2E4D127A01B8Q37703398-5100F065-169F-486F-83AE-B1E9CA9FA97BQ37763779-00A96620-6CDA-4383-B6E1-66E4FA431B8EQ37905787-4869C902-F11E-4BA5-B6E0-75CB4D465D1DQ37912251-DA4862EE-673F-4782-9DA1-693B8F20D6D4Q38059459-B17D16B0-AC8E-4575-A468-3FEC4CA186C2Q38100669-F9EF879F-FCA0-4E75-9CCB-A29CAACE8914Q38180018-68A3B177-A2CC-4691-82B0-91EE3380A771
P2860
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Skin thickness score as a pred ...... low-dose penicillamine trial.
@en
Skin thickness score as a pred ...... low-dose penicillamine trial.
@nl
type
label
Skin thickness score as a pred ...... low-dose penicillamine trial.
@en
Skin thickness score as a pred ...... low-dose penicillamine trial.
@nl
prefLabel
Skin thickness score as a pred ...... low-dose penicillamine trial.
@en
Skin thickness score as a pred ...... low-dose penicillamine trial.
@nl
P2093
P2860
P1476
Skin thickness score as a pred ...... low-dose penicillamine trial.
@en
P2093
Clements PJ
Hurwitz EL
P2860
P304
P356
10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q
P577
2000-11-01T00:00:00Z